This study conducted a questionnaire survey among 101 pharmaceutical enterprises to evaluate the policy awareness, implementation expectations, and obstacles encountered during the promotion of "Several Measures to Support the High-Quality Development of Innovative Drugs". The results indicate that the policy has a relatively significant promotional effect on innovative drug R&D. 30.69% of enterprises believed it significantly accelerated the market approval speed for innovative drugs, and 37.62% considered it highly favorable for market promotion. However, there is still room for improvement, including insufficient openness of healthcare insurance data, an overall low evaluation by enterprises regarding the current state of multi-channel payment capabilities for innovative drugs, a need for further optimization of the reimbursement list inclusion process, and limitations in clinical application. This study recommends that the government constructs a clinical value-oriented, full-chain policy ecosystem. Through measures such as refining innovation grading and pricing rules, strengthening multi-departmental coordination, eliminating barriers to drug use in medical institutions, guiding pharmaceutical enterprises to adjust their strategies focusing on value, and encouraging commercial insurance companies to build multi-payment and industry-supporting ecosystems, a more comprehensive full-chain support system for innovative drugs can be established. This will facilitate the better implementation and effectiveness of "Several Measures to Support the High-Quality Development of Innovative Drugs", transforming policy advantages into momentum for the high-quality development of the industry.